Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy

International Journal of Nanomedicine

Volumn 3, Issue 3, 2008, Pages 311-321

  Peng, Xiang Hong ^a   Qian, Ximei ^a   Mao, Hui ^a   Wang, Andrew Y ^b   Chen, Zhuo G ^a   Nie, Shuming ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OCEAN NANOTECH LLC   (United States)

Author keywords

Iron oxide nanoparticles; MRI; Therapy; Tumor imaging

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DEXTRAN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLATE RECEPTOR; GELATINASE A; GONADORELIN RECEPTOR; LIPOSOME; MACROGOL; MAGNETIC IRON OXIDE NANOPARTICLE; MEMBRANE ANTIGEN; METHOTREXATE; MEVINOLIN; MUCIN 1 ANTIGEN; NANOPARTICLE; STREPTAVIDIN; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERRIN RECEPTOR; TRASTUZUMAB; TUMOR MARKER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER DIAGNOSIS; CELL FUNCTION; CONTRAST ENHANCEMENT; DISEASE MARKER; DRUG RECEPTOR BINDING; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; HUMAN; IN VIVO STUDY; LIPOSOMAL DELIVERY; MACROPHAGE; MATERIAL COATING; METASTASIS; MICELLIZATION; MOLECULAR WEIGHT; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; ELECTROMAGNETIC FIELDS; FERRIC COMPOUNDS; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; NEOPLASMS;

EID: 67650648089     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Artemov D, Mori N, Okollie B, et al. 2003. MR molecular imaging of theHer-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med, 49:403-8.
2. Aslam M, Fu L, Li S, et al. 2005. Silica encapsulation and magnetic properties of FePt nanoparticles. J Colloid Interface Sci, 290:444-9.
3. Atri M. 2006. New technologies and directed agents for applications of cancer imaging. J Clin Oncol, 24:3299-308.
4. Bae Y, Diezi TA, Zhao A, et al. 2007. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release, 122:324-30.
5. Berry CC, Wells S, Charles S, et al. 2004. Cell response to dextran-derivatised iron oxide nanoparticles post internalisation. Biomaterials, 25:5405-13.
6. Bird CR, Drayer BP, Medina M, et al. 1988. Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. Radiology, 169:123-6.
7. Bradbury M, Hricak H. 2005. Molecular MR imaging in oncology. Magn Reson Imaging Clin N Am, 13:225-40.
8. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 54:631-51.
9. Bulte JW, Kraitchman DL. 2004. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed, 17:484-99.
10. Cerdan S, Lotscher HR, Kunnecke B, et al. 1989. Monoclonal antibody-coated magnetite particles as contrast agents in magnetic resonance imaging of tumors. Magn Reson Med, 12:151-63.
11. Chatzistamou L, Schally AV, Nagy A, et al. 2000. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin Cancer Res, 6:4158-65.
12. Chen H, Gu Y, Hub Y, et al. 2007. Characterization of pH- and temperature-sensitive hydrogel nanoparticles for controlled drug release. PDA J Pharm Sci Technol, 61:303-13.
13. Corot C, Robert P, Idee JM, et al. 2006. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev, 58:1471-504.
14. De Cuyper M, Joniau M. 1988. Magnetoliposomes. Formation and structural characterization. Eur Biophys J, 15:311-19.
15. DeNardo SJ, DeNardo GL, Miers LA, et al. 2005. Development of tumor targeting bioprobes ((111) In-chimeric L6 monoclonal antibody nanoparticles) for alternating magnetic field cancer therapy. Clin Cancer Res, 11(19 Pt 2):7087s-92s.
16. Deshane J, Garner CC, Sontheimer H. 2003. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem, 278:4135-44.
17. Fang C, Shi B, Pei YY, et al. 2006. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size." Eur J Pharm Sci, 27:27-36.
18. Funovics MA, Kapeller B, Hoeller C, et al. 2004. MR imaging of the her2/ neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging, 22:843-50.
19. Gang J, Park SB, Hyung W, et al. 2007. Magnetic poly epsilon-caprolactone nanoparticles containing Fe304 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target, 15:445-53.
20. Gao X, Cui Y, Levenson RM, et al. 2004. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol, 22:969-76.
21. Gupta AK, Gupta M. 2005. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 26:3995-4021.
22. Gupta AK, Naregalkar RR, Vaidya VD, et al. 2007. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed, 2:23-39.
23. Harisinghani MG, Barentsz J, Hahn PF, et al. 2003. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med, 348:2491-9.
24. Horak D, Babic M, Jendelova P, et al. 2007. D-mannose-modified iron oxide nanoparticles for stem cell labeling. Bioconjug Chem, 18:635-44.
25. Huh YM, Jun YW, Song HT, et al. 2005. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc, 127:12387-91.
26. Ito H. 2006. Oncology imaging: current status and new approaches. Int J Clin Oncol, 11:256-7.
27. Jain KK. 2005. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat, 4:645-50.
28. Jain TK, Morales MA, Sahoo SK, et al. 2005. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm, 2:194-205.
29. Jemal A, Siegel R, Ward E, et al. 2008. Cancer statistics, 2008. CA Cancer J Clin, 58:71-96.
30. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J Clin, 57:43-66.
31. Jinno H, Ueda M, Ozawa S, et al. 1996. Epidermal growth factor receptor-dependent cytotoxicity for human squamous carcinoma cell lines of a conjugate composed of human EGF and RNase 1. Life Sci, 58:1901-8.
32. Jodin L, Dupuis AC, Rouviere E, et al. 2006. Influence of the catalyst type on the growth of carbon nanotubes via methane chemical vapor deposition. J Phys Chem B, 110:7328-33.
33. Jordan A, Scholz R, Maier-Hauff K, et al. 2006. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol, 78:7-14.
34. Kale AA, Torchilin VP. 2007. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem, 18:363-70.
35. Kim D, Hong KS, Song J. 2007. The present status of cell tracking methods in animal models using magnetic resonance imaging technology. Mol Cells, 23:132-7.
36. Kohler N, Fryxell GE, Zhang M. 2004. A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. J Am Chem Soc, 126:7206-11.
37. Kohler N, Sun C, Wang J, et al. 2005. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir, 21:8858-64.
38. Kresse M, Wagner S, Pfefferer D, et al. 1998. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med, 40:236-42.
39. Kumagai M, Imai Y, Nakamura T, et al. 2007. Iron hydroxide nanoparticles coated with poly(ethylene glycol)-poly(aspartic acid) block copolymer as novel magnetic resonance contrast agents for in vivo cancer imaging. Colloids Surf B Biointerfaces, 56:174-81.
40. Kumar A, Sahoo B, Montpetit A, et al. 2007. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine, 3:132-7.
41. Laconte LE, Nitin N, Zurkiya O, et al. 2007. Coating thickness of magnetic iron oxide nanoparticles affects R(2) relaxivity. J Magn Reson Imaging, 26:1634-41.
42. Lanza GM, Wickline SA. 2003. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Probl Cardiol, 28:625-53.
43. Lanza GM, Winter P, Caruthers S, et al. 2004. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol, 5:495-507.
44. Lee H, Lee E, Kim do K, et al. 2006. Antibiofouling polymer-coated superparamagnetic iron oxide nanoparticles as potential magnetic resonance contrast agents for in vivo cancer imaging. J Am Chem Soc, 128:7383-9.
45. Lee H, Yu MK, Park S, et al. 2007a. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc, 129:12739-45.
46. Lee JH, Huh YM, Jun YW, et al. 2007b. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med. 13:95-9.
47. Lee SW, Chang DH, Shim MS, et al. 2007c. Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm Res, 24:1508-16.
48. Leuschner C, Kumar CS, Hansel W, et al. 2006. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat, 99:163-76.
49. Low PS, Henne, WA, Doorneweerd DD. 2008. Discovery and development of folic-Acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res, 41:120-9.
50. Maillard S, Ameller T, Gauduchon J, et al. 2005. Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J Steroid Biochem Mol Biol, 94:111-21.
51. Mikhaylova M, Kim DK, Bobrysheva N, et al. 2004. Superparamagnetism of magnetite nanoparticles: dependence on surface modification. Langmuir, 20:2472-7.
52. Montet X, Montet-Abou K, Reynolds F, et al. 2006. Nanoparticle imaging of integrins on tumor cells. Neoplasia, 8:214-22.
53. Moore A, Medarova Z, Potthast A, et al. 2004. In vivo targeting of under-glycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res, 64:1821-7.
54. Moore A, Weissleder R, Bogdanov A Jr. 1997. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging, 7:1140-5.
55. Nasongkla N, Bey E, Ren J, et al. 2006. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett, 6:2427-30.
56. Nie S, Xing Y, Kim GJ, et al. 2007. Nanotechnology applications in cancer. Annu Rev Biomed Eng, 9:257-88.
57. Nitin N, LaConte LE, Zurkiya O, et al. 2004. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem, 9:706-12.
58. Nurmi JT, Tratnyek PG, Sarathy V, et al. 2005. Characterization and properties of metallic iron nanoparticles: spectroscopy, electrochemistry, and kinetics. Environ Sci Technol, 39:1221-30.
59. Pinkernelle J, Teichgraber U, Neumann F, et al. 2005. Imaging of single human carcinoma cells in vitro using a clinical whole-body magnetic resonance scanner at 3.0 T. Magn Reson Med, 53:1187-92.
60. Racuciu M, Creanga DE, Airinei A. 2006. Citric-acid-coated magnetite nanoparticles for biological applications. Eur Phys J E Soft Matter, 21:117-21.
61. Reddy GR, Bhojani MS, McConville P, et al. 2006. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res, 12:6677-86.
62. Remsen LG, McCormick CI, Roman-Goldstein S, et al. 1996. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol, 17:411-18.
63. Rhyner MN, Smith AM, Gao X, et al. 2006. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomed, 1:209-17.
64. Rogers WJ, Basu P. 2005. Factors regulating macrophage endocytosis of nanoparticles: implications for targeted magnetic resonance plaque imaging. Atherosclerosis, 178:67-73.
65. Roser M, Fischer D, Kissel T. 1998. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm, 46:255-63.
66. Saul JM, Annapragada A, Natarajan JV, et al. 2003. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J Control Release, 92:49-67.
67. Sengupta S, Sasisekharan R. 2007. Exploiting nanotechnology to target cancer. Br J Cancer, 96:1315-19.
68. Serda RE, Adolphi NL, Bisoffi M, et al. 2007. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging, 6:277-88.
69. Shen T, Weissleder R, Papisov M, et al. 1993. Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med, 29:599-604.
70. Shenoy D, Little S, Langer R, et al. 2005. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res, 22:2107-14.
71. Shi X, Thomas TP, Myc LA, et al. 2007. Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys, 9:5712-20.
72. Simberg D, Duza T, Park JH, et al. 2007. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A, 104:932-6.
73. Sonvico F, Mornet S, Vasseur S, et al. 2005. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem, 16:1181-8.
74. Soroceanu L, Gillespie Y, Khazaeli MB, et al. 1998. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res, 58:4871-9.
75. Sun C, Sze R, Zhang M. 2006. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A, 78:550-7.
76. Sun C, Veiseh O, Gunn J, et al. 2008. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small, 4:372-9.
77. Thorek DL, Chen AK, Czupryna J, et al. 2006. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng, 34:23-38.
78. Tiefenauer LX, Tschirky A, Kuhne G, et al. 1996. In vivo evaluation of magnetite nanoparticles for use as a tumor contrast agent in MRI. Magn Reson Imaging, 14:391-402.
79. Toma A, Otsuji E, Kuriu Y, et al. 2005. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer, 93:131-6.
80. Uchida M, Flenniken ML, Allen M, et al. 2006. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc, 128:16626-33.
81. Veiseh M, Gabikian P, Bahrami SB, et al. 2007. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res, 67:6882-8.
82. Veiseh O, Sun C, Gunn J, et al. 2005. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett, 5:1003-8.
83. Wang MD, Shin DM, Simons JW, et al. 2007. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther, 7:833-7.
84. Wang YX, Hussain SM, Krestin GP. 2001. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol, 11:2319-31.
85. Yang J, Lee CH, Ko HJ, et al. 2007. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem Int Ed Engl, 46:8836-9.
86. Zhang C, Jugold M, Woenne EC, et al. 2007. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res, 67:1555-62.
87. Zhang Y, Kohler N, Zhang M. 2002. Surface modification of magnetite nanoparticles and their intracellular uptake. Biomaterials, 23:1553-61.